Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating
Published . Updated .
Fintel reports that on September 24, 2026, Goldman Sachs initiated coverage of United Therapeutics (NASDAQGS:UTHR) (BMV:UTHR) with a Sell recommendation.United Therapeutics Corporation, based in the United States, operates in the biotechnology sector, focusing on development and
Directly affected
Indirectly affected
- GBIL GOLDMAN SACHS ETF TR
GA selected GBIL as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GBND GOLDMAN SACHS ETF TR
GA selected GBND as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GCAL GOLDMAN SACHS ETF TR
GA selected GCAL as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GCOR GOLDMAN SACHS ACCESS U.S. AGGREGATE BOND ETF
GA selected GCOR as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEM GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY ETF
GA selected GEM as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GSBD GOLDMAN SACHS BDC INC SHS
GA selected GSBD as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on September 24, 2026, Goldman Sachs initiated coverage of United Therapeutics (NASDAQGS:UTHR) (BMV:UTHR) with a Sell recommendation.United Therapeutics Corporation, based in the United States, operates in the biotechno…
Source: Nasdaq Markets
How far United Therapeutics (UTHR) has moved since 24 Sep 2026
Since the first closing price after “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating,” United Therapeutics (UTHR) is +14.16%. The S&P 500 fund (SPY) is -0.62% over the same days, a +14.78% difference versus the market.
Official trades in United Therapeutics (UTHR) around 24 Sep 2026
- Maria Elvira Salazar sell Goldman Sachs Group (GS) ($1,001 - $15,000). The transaction date is the publication date. The filing is listed beside the story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.”
- Michael Rulli buy Goldman Sachs Group (GS) ($1,001 - $15,000). That is 21 days before publication, inside 30 days. The filing is listed beside the story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.”
- Gilbert Cisneros buy Goldman Sachs Group (GS) ($1,001 - $15,000). That is 29 days before publication, inside 30 days. The filing is listed beside the story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around United Therapeutics (UTHR)
Companies carried with this story
- UTHR United Therapeutics
In “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating,” United Therapeutics (UTHR) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names United Therapeutics Corp. in the headline; GA resolved that company to UTHR
- GS Goldman Sachs Group
Goldman Sachs Group (GS) is linked, with no stored direction, high confidence in the 24 Sep 2026 story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.” Reason on file: The reported development directly names GOLDMAN SACHS GROUP INC in the headline; GA resolved that company to GS
- GBIL Goldman Sachs Etf Tr
Goldman Sachs Etf Tr (GBIL) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.” Reason on file: GA selected GBIL as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GBND Goldman Sachs Etf Tr
In “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating,” Goldman Sachs Etf Tr (GBND) is linked, with no stored direction, medium confidence. Reason on file: GA selected GBND as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GCAL Goldman Sachs Etf Tr
Goldman Sachs Etf Tr (GCAL) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.” Reason on file: GA selected GCAL as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GCOR Goldman Sachs Access U.S. Aggregate Bond Etf
Goldman Sachs Access U.S. Aggregate Bond Etf (GCOR) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.” Reason on file: GA selected GCOR as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEM Goldman Sachs Activebeta Emerging Markets Equity Etf
In “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating,” Goldman Sachs Activebeta Emerging Markets Equity Etf (GEM) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEM as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GSBD Goldman Sachs BDC
Goldman Sachs BDC (GSBD) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating.” Reason on file: GA selected GSBD as a RELATED security because its canonical security name directly matches this event's themes: goldman, sachs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
United Therapeutics (UTHR)
On 24 Sep 2026, “Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating” is the story that connects United Therapeutics (UTHR) to this story.
For United Therapeutics (UTHR), the reason on file says The reported development directly names United Therapeutics Corp. in the headline; GA resolved that company to UTHR
Also listed, Goldman Sachs Group (GS): The reported development directly names GOLDMAN SACHS GROUP INC in the headline; GA resolved that company to GS
Dates in the story, and the United Therapeutics (UTHR) price range
GBIL traded between 99.83 and 100.11 across 20 sessions. The latest close on file is 100.03. GS traded between 859.56 and 967.15 across 20 sessions. The latest close on file is 875.50. UTHR traded between 468.97 and 585.67 across 20 sessions. The latest close on file is 542.98.
How strong the case is around United Therapeutics (UTHR)
46 out of 100
“Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating” scores 46 out of 100. The score uses 1 sources, and 8 linked companies.